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Abstract
Introduction Intravenous recombinant tissue plasminogen ac-
tivator (IV-rtPA) is given in acute ischemic stroke patients to
achieve reperfusion. Hemorrhagic transformation (HT) is a
serious complication of IV-rtPA treatment and related to
blood–brain barrier (BBB) injury. It is unclear whether HT
occurs secondary to reperfusion in combination with ischemic
BBB injury or is caused by the negative effect of IV-rtPA on
BBB integrity. The aim of this study was to establish the
association between reperfusion and the occurrence of HT.
Methods From the DUST study, patients were selected with
admission and follow-up non-contrast CT (NCCT) and CT
perfusion (CTP) imaging, and a perfusion deficit in the middle
cerebral artery territory on admission. Reperfusion was catego-
rized qualitatively as reperfusion or no-reperfusion by visual
comparison of admission and follow-up CTP. Occurrence of
HTwas assessed on follow-up NCCT. The association between
reperfusion and occurrence of HT on follow-up was estimated
by calculating odds ratios (ORs) and 95 % confidence intervals
(CIs) with additional stratification for IV-rtPA treatment.
Results Inclusion criteria were met in 299 patients. There was
no significant association between reperfusion and HT (OR
1.2 95%CI 0.5–3.1). In patients treated with IV-rtPA (n=203),
the OR was 1.3 (95%CI 0.4–4.0), and in patients not treated
with IV-rtPA (n=96), the OR was 0.8 (95%CI 0.1–4.5). HT
occurred in 14% of the IV-rtPA patients and in 7 % of patients
without IV-rtPA (95%CI of difference −1 to 14 %).
Conclusion Our results suggest that the increased risk of HT
after acute ischemic stroke treatment is not dependent on the
reperfusion status.
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Introduction
Timely restoration of the downstream capillary blood flow
(reperfusion) by recanalization of the occluded vessel in acute
ischemic stroke patients is associated with favorable clinical
outcome [1, 2]. However, reperfusion has also been associated
with the occurrence of hemorrhagic transformation (HT)
through a mechanism called reperfusion injury [1, 3–5]. HT
incorporates all types of post-ischemic hemorrhages, ranging
from the smaller hemorrhagic infarction (HI) type 1 or 2, to
the larger parenchymal hemorrhage (PH) type 1 or 2. Espe-
cially, the PH types may increase the risk of worse clinical
outcome [6–9]. To induce reperfusion and thereby improve
clinical outcome, intravenous recombinant tissue plasmino-
gen activator (IV-rtPA) can be given within 4.5 h after symp-
tom onset [10]. However, IV-rtPA also increases the risk of
HT by its thrombolytic action as well as by causing direct
damage to the blood–brain barrier (BBB) [10–13]. It is un-
clear whether HT after ischemic stroke is caused mainly by
reperfusion of an ischemic area with damage to the BBB or by
the detrimental effects of IV-rtPA on the BBB [3, 9]. To further
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explore this topic, first the relation between reperfusion and
the occurrence of HT needs to be investigated.
The purpose of this study was to investigate the association
between reperfusion and the occurrence of HT, both in pa-
tients treated with and without IV-rtPA.
Materials and methods
Study design
The Dutch acute stroke study (DUST) is a large prospective
multicenter cohort study that aims to assess the value of CT
perfusion (CTP) and CT angiography (CTA) in addition to pa-
tient characteristics and non-contrast CT (NCCT) for prediction
of outcome in patients with acute ischemic stroke
(ClinicalTrials.gov NCT00880113). Patients were included in
14 hospitals between May 2009 and August 2013 [14].
Inclusion criteria for the DUST were as follows: age
>18 years, suspected ischemic stroke of less than 9 h in dura-
tion, and National Institutes of Health Stroke Scale (NIHSS)
≥2, or 1 if an indication for IV-rtPA was present. Exclusion
criteria were known renal failure, contraindications for iodin-
ated contrast material, and hemorrhage or another diagnosis
seen on NCCT to explain the stroke symptoms. This study
was approved by the central medical ethics committee in the
University Medical Center (UMC) Utrecht and the local institu-
tional ethical review boards of the participating hospitals. Patients
or family gave signed informed consent unless a patient died
before consent could be obtained, in which case the need for
consent was waived by the medical ethics committee [14].
Patient selection
From the prospectively collected DUST database, patients
were retrospectively selected with (1) admission and follow-
up NCCT and CT perfusion and (2) a perfusion deficit in the
middle cerebral artery territory on admission CTP. Exclusion
criteria were as follows: (1) intra-arterial treatment, (2) poor
quality CTP, or (3) absence of one of the Alberta Stroke Pro-
gram Early CT Score (ASPECTS) levels on CTP. The inclu-
sion process is clarified in the flow chart (Fig. 1). Collected
clinical data were age, sex, history of stroke or hypertension,
NIHSS on admission, IV-rtPA treatment, and time from symp-
tom onset to admission CT scan series.
Imaging protocol and post-processing
In all DUST patients, NCCT, CTP, and CTAwere performed on
admission. Non-obligatory follow-up NCCT was planned after
3 days (±2 days) and also performed in case of clinical deterio-
ration. Additional follow-up CTA and CTP were performed if
possible. For the current study, patients were included only if
follow-up imaging was performed with NCCT and CTP. All
imaging studies were performed on multidetector CT scanners
ranging from 40 to 320 detectors. The CT protocol has been
described previously [14].
In short, the CTP involved successive gantry rotations in
cinemode during intravenous administration of iodinated con-
trast material (40 ml non-ionic contrast) followed by 40 ml of
saline, both with a flow of 6 ml/s. The CTP covered at least the
level of the basal ganglia to the lateral ventricles to be able to
assess ASPECTS levels 1 and 2, and compare between scan-
ners with different number of detectors [15].
From the acquired CTP data, color maps were created for
cerebral blood volume (CBV), cerebral blood flow (CBF),
mean transit time (MTT), and time to peak (TTP) utilizing
Fig. 1 Flow chart patient selection
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commercially available CTP software (Extended Brilliance
workstation 4.5, Philips Healthcare). This software uses a
deconvolution-based method which determines the MTT by
the difference in first moment of tissue and arterial time atten-
uation curves [16, 17]. To calculate the CBF from the MTT,
the software applies the central volume principle which is the
most accurate for low injection rates of iodinated contrast
material [18]. The internal carotid artery (if available in the
scan range) or anterior cerebral artery was chosen as arterial
input function [19]. The superior sagittal sinus was used as
venous output function.
All data and imaging processing was done centrally in the
UMCUtrecht. Scans were evaluated by one of three observers
with more than 5 years of stroke imaging experience (B.K.V.,
I.C.vd.S, J.W.D.). The side of symptoms was provided, but
observers were blinded to other clinical and imaging data.
Consensus was reached for ambiguous findings by an extra
review by two of the three radiologists, also blinded to other
clinical and imaging data. The number of consensus agree-
ment cases was not collected.
Reperfusion
Reperfusion status was analyzed by visual comparison of the
size of the perfusion abnormality on admission and follow-up
CTP maps for CBV, CBF, MTT, and TTP. Reperfusion was
classified qualitatively in a reperfusion and a no-reperfusion
group. No-reperfusion was defined as the absence of any vi-
sually apparent change in the size of the perfusion deficit on
follow-up CTP compared to the admission CTP. Partial reper-
fusion and hyperperfusion were included in the reperfusion
group and an enlarged or new perfusion deficit in the no-
reperfusion group.
Hemorrhagic transformation
The follow-up NCCTwas evaluated for the presence of hem-
orrhage. Hemorrhages were classified according to the Euro-
pean Cooperative Acute Stroke Study (ECASS)-1 criteria: HI-
1 (small petechiae along the margins of infarct), HI-2 (conflu-
ent petechiae within infarcted area but no space-occupying
effect), PH-1 (blood clots in 30 % or less of the infarcted area
with some slight space-occupying effect), and PH-2 (blood
clots of more than 30 % of infarcted area with substantial
space-occupying effect) [20, 7].
Statistical analysis
Patient characteristics were presented as number and percent-
ages, mean and standard deviation (SD), or median and inter-
quartile range (IQ). Differences between patients with and with-
out IV-rtPA treatment were tested with the χ2 test to compare
categorical variables and the Mann–Whitney U test for continu-
ous variables.
The primary outcome was occurrence of any HT (all
ECASS categories together). We estimated the association
between reperfusion and the occurrence of HT by calculating
odds ratios with 95 % confidence intervals (95%CIs) in the
total group of patients and in the sub-groups with and without
IV-rtPA treatment.
Results
From the DUST database of 1393 patients with complete admis-
sion data, 299 patients met inclusion criteria for this study. A total
of 36HTs (12%) occurred in this selected patient group (ECASS
HI-1, 13;HI-2, 15; PH-1, 7; and PH-2, 1). The overall percentage
was comparable to the percentage of HT in the whole DUST
database (11%). Themain reasons for exclusionwas the absence
of an ischemic deficit on admission CTP (n=732) or because no
follow-up CTP imaging was done (n=321). No significant dif-
ference was found in 3-month mRS between included and all
excluded patients.
Clinical and imaging characteristics are summarized in Ta-
ble 1. Treatment with IV-rtPA was given in 203 of the 299 pa-
tients (68 %). Patients treated with IV-rtPA less often had a prior
history of stroke or hypertension, had a significantly higher me-
dian NIHSS on admission (9 vs 6), and had a shorter median
time to scan than patients who did not receive IV-rtPA (84 vs
218 min).
Reperfusion (median assessed at day 3) was visible in 241
patients (81 %). There was no significant association between
HT and reperfusion status in all patients (odds ratio (OR) 1.2,
95%CI 0.5–3.1). Of the 36 (12 %) patients with HT, 29 re-
ceived IV-rtPA treatment and 7 did not. HT occurred twice as
often in patients treated with IV-rtPA compared to patients not
treated with IV-rtPA (14 vs 7 % with a 95%CI −1 to 14 % for
the difference). Both in patients treated with IV-rtPA and in
patients not treated with IV-rtPA, there was no significant
association between reperfusion and HT (OR 1.3 (95%CI
0.4–4.0) and OR 0.8 (95%CI 0.1–4.5), respectively).
The results of a sub-analysis show that of the 28 patients with
HI-type hemorrhages, 25 (89 %) showed reperfusion, while 3
(11 %) did not. Of the eight patients with PH type hemorrhage,
five (63 %) showed reperfusion while three (37 %) did not.
Discussion
The main finding in this study is that the overall occurrence of
hemorrhagic transformation 3 days after onset of acute ische-
mic stroke does not seem to be associated with reperfusion.
Our findings are in contradiction to Fiehler et al. 2005 who
suggested, in a retrospectiveMRI study in which HToccurred
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in 19 of the 51 patients, that HT in patients treated with IV-
rtPA might be caused by a higher incidence of local reperfu-
sion in the HT area [3]. However, in this study, no significant
difference in the occurrence of reperfusion between patients
with and without HT could be shown if the entire admission
perfusion abnormality area was considered. Moreover, the
definition of reperfusion used in that study was only based
on changes in TTP delay measured with MRI instead of CT,
which could lead to differences in measuring the infarct core
and penumbra and hence to different results [3]. Another ret-
rospective MRI study, with HT occurring in 22 of the 144
patients, stated that reperfusion was the most significant inde-
pendent predictor of early BBB disruption and that this BBB
disruption was an independent predictor of HT [21]. However,
they did not show a direct relation between reperfusion and
HT. BBB disruption was defined as post–gadolinium CSF
enhancement, a technique not frequently used in clinical prac-
tice. Moreover, only 25 % of their patients received IV-rtPA,
and no significant association between IV-rtPA and HT was
shown [21].
To our knowledge, our study is the largest prospectively col-
lected dataset to evaluate the association between reperfusion and
HT. The overall percentage of HT patients in our study was
within the range of previously published data on CT follow-up
literature [12, 22]. There was a clear difference in the occurrence
of HT between patients treated with IV-rtPA and patients not
treated with IV-rtPA, despite the absence of an association with
reperfusion. This might be an indication that the delivery of rtPA
to the ischemic area and not the reperfusion itself results in HT.
However, other factors like stroke severity or time to treatment
may also play a role.
Treatment with IV-rtPAwas given in 68 % of our patients.
This percentage is much higher compared to that of other
studies and possibly reflects the increased stroke awareness
in The Netherlands and subsequent shorter time to admission.
A selection bias in the DUST study with preference given to
inclusion of patients eligible for IV-rtPA treatment could also
be the reason for this higher percentage of treated patients.
The results of the sub-analysis of the HI-type and PH-type
hemorrhages suggest that there is a trend toward a higher
perfusion rate in patients developing HI-type hemorrhages,
while PH-type hemorrhages seem less related to reperfusion.
This is in accordance with the findings of ECASS-2 which
showed better outcomes with HI-type hemorrhage and worse
outcomes with PH-type hemorrhages, possibly related to re-
perfusion status [23]. Unfortunately, the numbers in the sub-
analysis are too low to perform meaningful statistical analysis
on these sub-groups. As we already derived our population
from the whole DUST database, we were unable to test this in
a larger cohort of patients.
Although we did not show a relation between reperfusion
and the occurrence of hemorrhagic transformation, it is possi-
ble that this is due to the fact that the exact location of the
hemorrhage is difficult to ascertain and that the reperfusion in
a very focal area could be of importance. It could be argued
that with the use of higher-resolution thin-sliced CTP and
added filtering and noise reduction, this relationship could
be better determined in future studies [24].
This study has some limitations. First, although the overall
number of hemorrhages was comparable to previously pub-
lished data, the number of symptomatic hemorrhages (defined
as PH-2) in this series is low compared to that in some other









Age, median (IQ) 68 (58–77) 68 (56–75) 70 (61–78) 0.10
Female sex, n (% ) 116 (39) 79 (39) 37 (39) 0.95
Prior stroke, n (% ) 68 (23) 35 (17) 33 (34) 0.001*
Hypertension, n (% ) 154 (52) 95 (47) 59 (62) 0.02*
NIHSS, median (IQ) 8 (5–14) 9 (6–15) 6 (3–12) 0.002*
Imaging parameters
Time to admission scan, minutes, median (IQ) 103 (65–163) 84 (60–133) 218 (133–315) 0.006*
NCCT
HT, n (%) 36 (12) 29 (14) 7 (7) 0.08
CTP
No reperfusion, n (%) 58 (19) 34 (17) 24 (25) 0.09
χ2 test was used to compare categorical variables and Mann–Whitney U test for continuous variables
CTP CT perfusion, HT hemorrhagic transformation, IQ interquartile range, NCCT non-contrast CT, NIHSS National Institutes of Health Stroke Scale,
rtPA recombinant tissue plasminogen activator
*P<0.05
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studies [25, 22]. Most symptomatic hemorrhages (n=23) are not
included because the inclusion criteria for this study required a
CTP at follow-up. Patients with symptomatic HTmay have been
too agitated or hemodynamically unstable to lie still long enough
to perform this follow-up CTP, and many of the PH-2 outcomes
from the DUST database could not be included in this analysis
because follow-up CTP was missing. Another explanation for
the low number of PH-2’s may be the relatively short time to
treatment in our study. It is known that longer time to treatment is
related to occurrence of HT [25]. We included smaller hemor-
rhages (HI-1 and HI-2) in our analysis since they are also related
to poor outcome in larger studies [26–28]. Nevertheless, due to
the low number of PH-2, our results must be interpreted with
caution and are mainly applicable for populations with smaller
hemorrhages.
Second, the timing of most follow-up scans was around
3 days. Reperfusion and recanalization are known to continue
up to several weeks but the Btime is brain^ concept states that
reperfusion is only relevant if it occurs within several hours
after onset of ischemia [29]. It could be argued that reperfu-
sion measurement at an earlier time point would be more
appropriate. But, for practical purposes and to minimize dis-
comfort for participating patients, we had to compromise be-
tween timing of HT detection and early reperfusion assess-
ment. Moreover, because patients did receive an additional
NCCT in case of clinical deterioration after the scheduled
follow-up scans were made, it is unlikely that significant hem-
orrhages were missed.
Third, we excluded patients with intra-arterial treatment as
most of these patients were treated with a combination of me-
chanical thrombectomy and intra-arterial thrombolysis, which
probably has an added but unknown effect on the integrity of
the BBB.
Fourth, reperfusion status was not quantitatively assessed but
dichotomized as reperfusion or no-reperfusion by visual compar-
ison of the admission and follow-upCTP images. Little is known
about the quantitative assessment of reperfusion with CTP, and
no universal thresholds for the assessment of change of CTP
deficits are available. Moreover, the discrepancy rate for quanti-
tative assessment of reperfusion with the TIMI reperfusion score
on angiography has been described to be as high as 41 %, which
seems to justify using a simple qualitative assessment [30]. Qual-
itative interpretation of CTP has shown good to excellent agree-
ment rates between observers [31–33].
Conclusion
The occurrence of hemorrhagic transformation does not seem to
be associated with reperfusion. This suggests that other causes,
like ischemic injury or the effects of IV-rtPA, are more important
in the occurrence of hemorrhagic transformation in acute ische-
mic stroke.
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